New Patient Resources on EpilepsyAdvocate.com Unveiled in Honor of Epilepsy Awareness Month

ATLANTA, Nov. 22, 2010 /PRNewswire/ -- New stories and insights from the epilepsy community have been unveiled on EpilepsyAdvocate.com, including new interviews on "Women Succeeding with Epilepsy" and Epilepsy Advocate Radio. These programs represent UCB's continued commitment to the epilepsy community and seek to both empower patients and raise awareness about the condition.

NEW WEBISODES FOR WOMEN!

  • Two new video interviews are available featuring Epilepsy Advocates Amy Wyatt and Veronica Crowe and their individual accounts of successfully overcoming obstacles posed by epilepsy.
  • These videos are part of the "Women Succeeding with Epilepsy" program which features real women sharing personal stories of the impact of epilepsy on both patients and caregivers.
  • The program launched earlier this year, and was developed in conjunction with HealthyWomen, the leading online health information source for women. Click here to view these interviews.

NEW EPILEPSY ADVOCATE RADIO SHOW!

  • A new edition of Epilepsy Advocate Radio, an internet radio show features host Chris Maxwell interviewing:
    • LaKeisha Parnell, UCB Family Epilepsy Scholarship recipient
    • Tib Holland from Canine Assistants who explains how seizure response dogs can bring independence to people living with epilepsy,
    • Amy Wyatt, who discusses the tremendous impact that Lucia – their seizure response dog – has had on her family's daily lives.
  • Click here to access the "Epilepsy Advocate Radio" player at the bottom-left of the screen.
  • SHARE Epilepsy Advocate by clicking on the share button on the player and selecting one of the social media tools; email to a friend, Facebook and/or Twitter.

About Epilepsy Advocate™

Created by UCB in 2006, the Epilepsy Advocate™ program offers opportunities to learn more about epilepsy and how to manage the condition. Epilepsy Advocates are people living with epilepsy and caregivers who share their success stories with a goal of inspiring individuals in the epilepsy community to seek the best possible care and make positive changes in their lives.

To date, over 15,000 people impacted by epilepsy have connected with Epilepsy Advocates at more than 300 live programs across the U.S. Additionally, EpilepsyAdvocate.com and Facebook.com/EpilepsyAdvocate offer a wide variety of resources, including an engaging online radio program and motivational videos, for anyone looking for more information about epilepsy.

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and three million people in the U.S.—making it more common than multiple sclerosis and Parkinson's disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and is defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Roughly 20-30 percent of people living with epilepsy have either uncontrolled seizures or significant side effects secondary to medication. This highlights the ongoing need for the development of new epilepsy therapies. For more information about epilepsy, visit EpilepsyAdvocate.com.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB). UCB's U.S. headquarters has been located in Smyrna, GA since 1995.

The Epilepsy Company™, Epilepsy Advocate™, UCB Family Epilepsy Scholarship Program™ are trademarks of the UCB group of companies.

Further Information

Andrea Levin, Senior Manager, Communications & PR, CNS, UCB, Inc.

T: 770.970.8352 / E: [email protected]



SOURCE UCB